Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130060 · ClinicalTrials.gov registry record · Phase 1
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05130060: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT05130060 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05130060, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase Ib trial studies the safety and side effects of a vaccine (PolyPEPI1018 vaccine) in combination with TAS-102 in treating patients with colorectal that has spread to other parts of the body (metastatic). PolyPEPI1018 peptide vaccine is used to immunize against proteins present on the surface of tumor cells. This vaccine can activate the body's immune cells, called T cells. T cells fight infections and can also kill cancer cells. TAS-102 may help block the formation of growths that may become cancer. Giving PolyPEPI1018 and TAS-102 may kill more tumor cells in patients with metastatic colorectal cancer.
Interventions
- DRUG Trifluridine and Tipiracil Hydrochloride
- BIOLOGICAL Colorectal Cancer Peptide Vaccine PolyPEPI1018
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2023-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05130060
The ClinicalTrials.gov registry entry for NCT05130060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trifluridine and Tipiracil Hydrochloride is the first listed.
NCT05130060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05130060 about?
NCT05130060 is a clinical study titled "A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer". This phase Ib trial studies the safety and side effects of a vaccine (PolyPEPI1018 vaccine) in combination with TAS-102 in treating patients with colorectal that has spread to other parts of the body (metastatic). PolyPEPI1018 peptide vaccine is used to immunize against proteins present on the surfa...
What is the current status of trial NCT05130060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-01-10. Estimated completion is 2023-06-11.
What interventions are being tested in trial NCT05130060?
The interventions under investigation include: Trifluridine and Tipiracil Hydrochloride (DRUG), Colorectal Cancer Peptide Vaccine PolyPEPI1018 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05130060?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.